BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) gets fund from NIAID


Dallas, Texas 10/08/2013 (Financialstrend) – On September 17, Wells Forgo analysts had commented that the news of “National Institute of Allergy and Infectious Diseases” to fund BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) further development of BCX4430 as a very positive development. The target drug is being designed to develop a “RNA polymerase inhibitor” which can be used to treat patients suffering form “Marburg virus.”

“National Institute of Allergy and Infectious Diseases” board has set stiff goals for BCRX to achieve in exchange of the funding. The first goal would be for BCRX to file “IND” on both the “intravenous and intramuscular” mode of administering the drug into the patients. On completion, the second goal prescribes a Phase 1 clinical trial to be launched for the same.

In exchange, the biotechnology firm will get a upfront payment of $5 million. On meeting of the mile stone goals discussed above, BCRX will have the option to seek upwards of an additional $22 million. The two organizations have set a extended goal of five years for the project completion. On the back of this news, the share price of the stock had rocketed up by 6.6%.

The shares of the stock have appreciated by a humongous 344% in the past 90 days and by close to 407% in the last 9 months. As of close of business on October 7, the stock is trading a $7.2 per share. This translates to a 566% increase in its valuations from the 52 week low pricing of $1.08 per share. The company has managed to post sales of $14.2 million in the previous 12 months and has accumulated $37 million over the same period.  At these increased valuations, it market cap has gone up to $384 million and has recorded  significant  gains for its investors in comparison to other drug firms which are of similar market cap as itself.

This report is for information purposes only, and is neither a solicitation or recommendation to buy nor an offer to sell securities. Financials Trend is not-a-registered-investment-advisor. Financials Trend is not a broker-dealer. Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. Financials Trend accepts no liability for any losses arising from an investor's reliance on the use of this material. Financials Trend sometimes gets compensated up to one hundred and fifty thousand dollars per month for featuring particular stocks. See site disclaimer for complete compensation. Financials Trend and its affiliates or officers currently hold no shares of these stocks. Financials Trend and its affiliates or officers will purchase and sell shares of common stock of these stocks, in the open market at any time without notice. Financials Trend will not update its purchases and sales of these stocks in any future postings on Financials Trend's websites. Certain information included herein is forward-looking within the context of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. The words "may", "would," "will," "expect," "estimate," "anticipate," "believe," "intend," " project," and similar expressions and variations thereof are intended to identify for ward-looking statements. Such forward- looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. *Financials Trend does not set price targets on securities. Never invest into a stock discussed on this web site or in this email alert unless you can afford to lose your entire investment.